despit
import
reduct
report
malaria
incid
last
decad
number
countri
worldwid
malaria
infect
still
repres
one
major
global
public
health
threat
world
health
organ
estim
annual
global
burden
million
malaria
case
death
least
six
differ
malaria
parasit
speci
transmit
human
plasmodium
vivax
second
parasit
speci
epidemiolog
import
million
case
estim
per
year
worldwid
malariaendem
area
coexist
p
falciparum
thu
make
control
difficult
due
limit
impact
cyclic
loss
effect
classic
malaria
control
measur
base
multipl
evid
feasibl
malaria
vaccin
signific
effort
invest
develop
malaria
subunit
vaccin
past
decad
signific
progress
achiev
p
falciparum
sever
vaccin
candid
current
clinic
develop
one
consid
licensur
contrast
develop
p
vivax
vaccin
significantli
neglect
candid
select
clinic
test
p
vivax
antigen
consid
vaccin
potenti
test
vitro
studi
well
preliminari
preclin
studi
mice
primat
antigen
select
classic
immunoserolog
method
undergon
phase
clinic
trial
past
number
parasit
antigen
avail
vaccin
studi
quit
limit
present
advanc
establish
plasmodium
genom
proteom
togeth
high
throughout
laboratori
techniqu
potenti
acceler
develop
malaria
vaccin
addit
use
bioinformat
tool
explor
malaria
genomeproteom
databas
allow
new
approach
identif
parasit
protein
contain
coil
coil
domain
domain
readili
fold
stabl
structur
capabl
elicit
antibodi
reactiv
structur
nativ
epitop
gener
monomorph
structur
capac
block
critic
function
medic
import
microorgan
specif
p
falciparum
antigen
contain
domain
involv
antibodydepend
inhibit
malaria
parasit
growth
therefor
repres
target
vaccin
develop
thu
drastic
reduc
time
requir
antigen
select
preclin
test
past
year
approxim
p
falciparum
coil
coil
protein
fragment
assess
combin
genomewid
bioinformat
analysi
peptid
select
peptid
chemic
synthesi
immun
biochem
assay
vitro
function
assay
associ
protect
analysi
unpublish
data
total
put
coilcontain
protein
amino
acid
length
identifi
new
target
protein
p
falciparum
asexu
blood
stage
describ
studi
carri
use
technolog
approach
p
vivax
antigen
ortholog
p
falciparum
evalu
antigen
use
human
sera
immunogen
mice
orthologu
good
candid
multispeci
vaccin
potenti
elicit
antigen
reaction
speci
includ
search
paramet
p
vivax
salvador
genom
databas
plasmodb
use
select
p
vivax
ortholog
p
falciparum
protein
sequenc
asexu
blood
stage
contain
coil
coil
structur
analyz
coil
softwar
fifti
p
vivax
orthologu
found
least
homolog
p
falciparum
coiledcoil
protein
previous
identifi
sequenc
maxim
length
possibl
order
maxim
stabil
conform
increas
array
conform
epitop
could
yield
select
coil
coilcontain
protein
character
possibl
surfac
locat
gpi
anchor
use
follow
softwar
identif
potenti
signal
peptid
secretomep
signalp
http
wwwcbsdtudkservic
transmembran
span
region
tmpred
http
wwwchembnetorg
softwaretmpredrmhtml
tmhmm
http
wwwcbsdtudkservicestmhmm
gpianchor
protein
http
mendelimpunivieacatsatgpigpiserverhtml
predict
subcellular
local
ptarget
addit
major
histocompat
complex
protein
mhcii
bind
predict
made
use
iedb
analysi
resourc
consensu
tool
combin
predict
ann
aka
netmhc
smm
comblib
within
sequenc
preselect
peptid
use
murin
immunogen
studi
fifti
p
vivax
polypeptid
amino
acid
long
synthes
fluorenylmethoxycarbonyl
fmoc
solidphas
chemistri
use
intavi
ag
bioanalyt
synthes
germani
tabl
result
construct
hplcpurifi
puriti
confirm
analyt
hplc
mass
spectrometri
malditof
appli
biosystem
foster
citi
ca
reagent
purchas
fluka
buch
switzerland
novabiochem
laufelfingen
switzerland
addit
five
p
falciparum
polypeptid
describ
previous
use
test
crossreact
p
vivax
p
falciparum
speci
spectra
peptid
record
jasco
spectromet
jasco
corpor
tokyo
japan
equip
temperatur
control
cm
path
length
cuvett
measur
made
water
ph
peptid
concentr
mgml
human
serum
sampl
adult
live
malariaendem
area
colombia
papua
new
guinea
png
well
nonendem
area
switzerland
use
assess
peptid
antigen
sera
n
collect
maprik
district
east
sepik
provinc
malariaendem
region
png
crosssect
survey
describ
previous
wherea
colombian
sampl
n
obtain
two
geograph
distant
epidemiolog
differ
malariaendem
site
tumaco
state
n
tierralta
state
n
previou
infect
p
vivax
confirm
base
posit
p
vivax
bloodstag
immunofluoresc
antibodi
test
ifat
result
ethic
clearanc
studi
obtain
png
medic
research
advisori
committe
well
institut
review
board
irb
malaria
vaccin
drug
develop
ceciv
cali
colombia
written
inform
consent
ic
obtain
volunt
neg
control
sampl
obtain
swiss
adult
donor
histori
malaria
previou
travel
malariaendem
area
human
antibodi
specif
affinitypurifi
pool
human
serum
sampl
adult
live
burkina
faso
use
test
crossreact
respect
p
vivax
orthologu
fiveweek
old
femal
balbc
mice
maintain
facil
mvdc
handl
accord
institut
guidelin
divid
eight
group
four
anim
mice
inject
three
time
select
antigen
formul
montanid
isa
adjuv
seppic
inc
pari
franc
mous
inject
subcutan
base
tail
peptid
formul
final
volum
day
approxim
whole
blood
collect
eight
day
first
immun
ten
day
second
third
immun
anesthesia
orbit
sinu
antibodi
respons
measur
elisa
describ
previous
twenti
day
final
immun
mice
euthan
anesthet
inhal
spleen
lymph
node
asept
remov
mononuclear
cell
obtain
lymph
node
spleen
macer
follow
separ
use
ficollhystopaqu
gradient
cell
assay
immedi
product
mononuclear
cell
determin
use
specif
elispot
assay
describ
studi
carri
strict
accord
institut
guidelin
protocol
approv
committe
ethic
anim
experi
universidad
del
vall
permit
number
surgeri
perform
anesthesia
effort
made
minim
suffer
antibodi
respons
test
antigen
measur
human
murin
sera
elisa
describ
previous
briefli
elisa
plate
nuncimmuno
plate
thermo
usa
coat
respect
polypeptid
overnight
plate
block
skim
milk
pbst
ph
h
room
temperatur
wash
plate
incub
h
room
temperatur
sera
sampl
prepar
skimmilk
follow
human
sera
test
dilut
wherea
murin
sera
test
threefold
serial
dilut
start
igg
antibodi
detect
use
alkalin
phosphataseconjug
antihuman
antimous
immunoglobulin
sigma
chemic
co
st
loui
mo
dilut
enzymat
activ
develop
incub
min
room
temperatur
paranitrophenyl
phosphat
substrat
final
reaction
read
nm
micropl
reader
mrx
dynex
technolog
inc
chantilli
va
cutoff
point
calcul
three
sd
mean
absorb
valu
sera
healthi
malaria
swiss
volunt
mice
respect
posit
respond
classifi
accord
od
ratio
od
valu
test
sampl
divid
cutoff
valu
result
consid
posit
absorb
test
sera
higher
equal
cutoff
point
elisa
experi
perform
duplic
two
independ
experi
sinc
fragment
ortholog
p
falciparum
test
crossreact
speci
use
p
falciparum
antigen
sera
mice
immun
p
vivax
coil
coil
fragment
likewis
test
p
vivax
fragment
affinitypurifi
human
igg
specif
two
p
falciparum
fragment
previous
shown
capac
induc
strong
monocytedepend
parasit
kill
neg
control
differ
coil
coil
nonrel
antigen
use
parasit
recognit
antipeptid
antibodi
determin
ifat
use
antigen
p
vivax
blood
stage
obtain
colombian
patient
mous
sera
collect
day
last
peptid
immun
briefli
parasit
incub
sera
dilut
reaction
develop
fluoresceinconjug
goat
antimous
igg
jackson
immunoresearch
laboratori
inc
baltimor
md
dilut
slide
mount
glycerol
examin
nikon
eclips
microscop
epifluoresc
p
falciparum
parasit
crossreact
also
determin
ifat
use
antigen
bloodstag
parasit
deriv
vitro
cultur
determin
potenti
eight
select
peptid
stimul
tcell
respons
vitro
lymph
node
splenocyt
obtain
immun
mice
quantifi
purpos
commerci
mous
elispot
kit
mabtech
ab
stockholm
sweden
use
test
carri
accord
manufactur
instruct
multiscreen
plate
millipor
bedford
coat
overnight
room
temperatur
antimous
antibodi
rpmi
medium
contain
fetal
bovin
serum
fb
gibco
use
block
solut
freshli
isol
mononuclear
cell
plate
duplic
well
cell
rpmi
medium
supplement
fb
cultur
medium
alon
conconavalin
synthet
peptideml
medium
ad
plate
cultur
h
humidifi
atmospher
wash
biotinyl
antibodi
ad
incub
h
room
temperatur
plate
wash
alkalin
phosphatasestreptavidin
mabtech
ab
stockholm
sweden
ad
spot
visual
ad
bcipnbt
sigma
scan
count
use
aid
elispot
reader
aid
autoimmun
diagnostika
gmbh
germani
determin
number
spotswel
result
express
mean
number
spotform
cell
sfc
per
cell
fisher
exact
test
conting
tabl
use
compar
differ
seropreval
png
colombian
group
anova
test
use
compar
group
dunnett
multipl
comparison
test
use
posthoc
analysi
p
valu
consid
statist
signific
statist
analys
perform
use
graphpad
prism
softwar
version
graphpad
softwar
inc
san
diego
ca
usa
total
p
vivax
fragment
residu
long
contain
coil
coil
motif
select
base
proteom
transcriptom
data
p
falciparum
orthologu
present
erythrocyt
parasit
stage
tabl
variabl
homolog
ident
observ
p
falciparum
correspond
p
vivax
fragment
tabl
antigen
greater
homolog
identif
potenti
signal
peptid
transmembran
tm
region
gpianchor
subcellular
local
predict
reveal
five
protein
contain
tm
domain
anoth
three
involv
secretori
pathway
latter
peptid
also
contain
signal
peptid
one
protein
predict
locat
mitochondria
none
contain
gpi
anchor
circular
dichroism
cd
studi
randomli
select
peptid
indic
assum
total
partial
conform
water
peptid
exhibit
cd
pattern
characterist
high
content
indic
figur
wherea
remain
peptid
show
cd
profil
similar
shown
peptid
figur
intermedi
shown
figur
characterist
partial
organ
coil
coil
peptid
test
elisa
use
human
sera
recogn
png
n
sera
variabl
preval
howev
case
preval
antigen
display
reactiv
see
tabl
addit
peptid
show
preval
png
sampl
test
colombian
sera
peptid
antigen
variabl
preval
tabl
ten
peptid
test
human
colombian
sera
sampl
display
high
degre
recognit
rang
recognit
peptid
png
sera
rang
wherea
recognit
colombian
sera
peptid
vari
interestingli
seven
select
peptid
antigen
respond
png
four
peptid
reactiv
colombian
sera
tabl
differ
reactiv
also
observ
two
malariaendem
site
colombia
tierralta
tumaco
data
shown
respons
peptid
stronger
png
compar
colombian
sera
present
od
ratio
tabl
eight
peptid
show
preval
either
png
colombian
sera
test
immunogen
balbc
mice
immun
mice
develop
specif
igg
antibodi
coil
coil
fragment
second
immun
dose
determin
elisa
except
immun
three
immun
dose
need
produc
detect
antibodi
level
figur
antibodi
titer
increas
steadili
titer
rang
third
immun
tabl
mice
immun
show
variabl
respons
uniform
anim
two
anim
group
fail
develop
typic
boost
respons
third
dose
antibodi
titer
decreas
becam
neg
remain
stabl
neither
recogn
nativ
protein
ifat
tabl
howev
sera
four
eight
immun
group
abl
recogn
nativ
protein
p
vivax
asexu
blood
stage
ifat
assay
dilut
two
show
strong
reactiv
tabl
control
mice
receiv
adjuv
salin
solut
nonrespons
indic
elisa
ifat
data
shown
sera
mice
immun
reactiv
correspond
orthologu
similar
reactiv
indic
compar
control
sampl
figur
none
antigen
show
signific
crossreact
moreov
crossreact
also
observ
specif
affinitypurifi
human
igg
test
correspond
p
vivax
orthologu
threefold
less
reactiv
observ
case
compar
posit
control
addit
crossreact
whole
p
falciparum
parasit
observ
ifat
tabl
relationship
observ
homolog
reactiv
sinc
fragment
low
ident
highli
reactiv
p
vivax
fragment
p
falciparum
parasit
wherea
greater
homolog
reactiv
tabl
tcell
product
induc
six
eight
peptid
test
elispot
recogn
murin
lymphocyt
tabl
greatest
product
induc
mean
sfc
respect
follow
mean
sfc
respect
figur
addit
select
peptid
present
potenti
epitop
amino
acid
sequenc
confirm
bioinformat
analysi
tabl
appar
relat
observ
affin
predict
epitop
result
obtain
mous
epitop
describ
tabl
higher
affin
defin
lower
percentil
rank
observ
epitop
allel
human
test
higher
affin
observ
case
compar
mous
epitop
although
differ
observ
main
epitop
found
epitop
predict
mous
allel
could
present
human
allel
lower
affin
attempt
identifi
new
target
parasit
antigen
malaria
vaccin
develop
bioinformat
tool
previous
use
select
protein
contain
coil
coil
motif
p
falciparum
protein
studi
similar
algorithm
use
pilot
search
p
falciparum
ortholog
antigen
p
vivax
genom
coil
coil
p
vivax
segment
show
high
degre
homolog
previous
identifi
ortholog
p
falciparum
fragment
select
assess
antigen
immunogen
studi
end
four
antigen
identifi
potenti
target
addit
test
vaccin
candid
figur
interest
note
fragment
test
contain
coil
recogn
sera
individu
live
p
vivax
endem
area
png
colombia
fragment
antigen
variabl
preval
depend
origin
serum
sampl
variat
reactiv
among
sera
appear
associ
mainli
distinct
malaria
transmiss
condit
two
region
wherea
png
highli
endem
p
vivax
account
larg
proport
malaria
case
colombia
low
moder
malariaendem
region
p
vivax
preval
plasmodium
parasit
howev
factor
differ
genet
background
host
parasit
transmiss
rate
may
also
explain
differ
observ
recognit
frequenc
result
similar
found
previou
studi
differ
reactiv
observ
antigen
test
sera
differ
endem
area
addit
promis
find
eight
peptid
fragment
abl
induc
signific
antibodi
respons
immun
mice
concomit
induct
produc
tcell
six
peptid
furthermor
specif
antibodi
four
fragment
result
posit
reaction
ifa
assay
use
p
vivax
blood
stage
parasit
two
antibodi
also
reactiv
p
falciparum
ortholog
antigen
although
none
reactiv
p
falciparum
parasit
antigen
hand
affin
purifi
human
antibodi
specif
two
p
falciparum
antigen
reactiv
p
vivax
parasit
antigen
eight
preselect
antigen
induc
antibodi
respons
although
variabl
degre
regard
antibodi
titer
antibodi
kinet
similar
result
obtain
previou
studi
use
p
falciparum
ortholog
antigen
elicit
variabl
intermediateto
high
antibodi
respons
respons
seem
associ
fragment
length
sinc
strong
antibodi
titer
observ
respons
smaller
fragment
howev
four
peptid
induc
antibodi
mice
abl
react
whole
p
vivax
parasit
four
peptid
induc
strongest
antibodi
respons
peptid
chromosomeassoci
protein
two
hypothet
protein
interestingli
antibodi
crossreact
ortholog
p
falciparum
antigen
could
repres
clear
advantag
multispeci
malaria
vaccin
develop
provid
cross
reactiv
also
observ
p
falciparum
parasit
protein
addit
consid
interest
previous
describ
promis
malaria
vaccin
candid
also
test
crossreact
antigen
sera
mice
immun
specif
purifi
human
igg
reactiv
homolog
two
peptid
variabl
respect
surprisingli
share
ident
correspond
orthologu
show
crossreact
interestingli
shown
reactiv
purifi
human
igg
howev
convers
p
falciparum
antigen
reactiv
mous
sera
none
antibodi
p
vivax
antigen
test
show
crossreact
nativ
protein
blood
stage
detect
ifat
possibl
due
lower
sensit
test
due
mixtur
stage
present
donor
sampl
low
protein
express
peptid
induc
strong
product
expect
presenc
mhcii
epitop
predict
bioinformat
analysi
induc
higher
level
along
strong
antibodi
respons
induc
detect
product
agreement
low
affin
cell
epitop
predict
assess
iedb
analysi
resourc
consensu
tool
worthi
note
peptid
induc
greatest
product
also
induc
strongest
antibodi
respons
indic
great
potenti
vaccin
develop
sinc
associ
observ
mous
human
predict
epitop
addit
experi
perform
nonhuman
primat
assess
cell
immun
respons
antigen
transmembran
segment
involv
secretori
pathway
found
poorli
antigen
suggest
fragment
may
express
parasit
surfac
present
suffici
concentr
allow
recognit
investig
warrant
determin
actual
local
correspond
antigen
although
antigen
fragment
associ
transmembran
domain
two
involv
secretori
pathway
shown
solubl
protein
releas
time
schizont
ruptur
equal
effect
trigger
immun
respons
though
desir
function
activ
antibodi
elicit
mice
human
measur
parasit
growth
inhibit
assay
could
perform
due
lack
p
vivax
vitro
cultur
preclin
studi
includ
experiment
infect
nonhuman
primat
must
carri
address
question
taken
togeth
present
data
along
previous
publish
point
coil
coil
peptid
import
potenti
sourc
malaria
vaccin
candid
analysi
coil
coil
motif
extend
entir
group
erythrocyt
parasit
antigen
polysubunit
antigen
design
contain
relev
p
vivax
p
falciparum
fragment
capabl
induc
effect
immun
respons
thu
studi
direct
relev
p
vivax
asexu
blood
stage
vaccin
design
suggest
antigen
test
could
effect
differ
malaria
set
png
colombia
